Abstract

Beta-arrestin1 is an adapter/scaffold for many G protein-coupled receptors during mitogen-activated protein kinase signaling. Phosphorylation of beta-arrestin1 at position Ser-412 is a regulator of beta-arrestin1 function, and in the present study, we showed that insulin led to a time- and dose-dependent increase in beta-arrestin1 Ser-412 phosphorylation, which blocked isoproterenol- and lysophosphatidic acid-induced Ser-412 dephosphorylation and impaired ERK signaling by these G protein-coupled receptor ligands. Insulin treatment also led to accumulation of Ser-412-phosphorylated beta-arrestin1 at the insulin-like growth factor 1 receptor and prevented insulin-like growth factor 1/Src association. Insulin-induced Ser-412 phosphorylation was partially dependent on ERK as treatment with the MEK inhibitor PD98059 inhibited the insulin effect (62% reduction, p = 0.03). Inhibition of phosphatidylinositol 3-kinase by wortmannin did not have a significant effect (9% reduction, p = 0.41). We also found that the protein phosphatase 2A (PP2A) was in a molecular complex with beta-arrestin1 and that the PP2A inhibitor okadaic acid increased Ser-412 phosphorylation. Concomitant addition of insulin and okadaic acid did not produce an additive effect on Ser-412 phosphorylation, suggesting a common mechanism. Small t antigen specifically inhibited PP2A, and in HIRcB cells expressing small t antigen, beta-arrestin1 Ser-412 phosphorylation was increased, and insulin had no further effect. Insulin treatment caused increased beta-arrestin1 Ser-412 phosphorylation, which blocked mitogen-activated protein kinase signaling and internalization by beta-arrestin1-dependent receptors with no effect on beta-adrenergic receptor Gs-mediated cAMP production. These findings provide a new mechanism for insulin-induced desensitization of ERK activation by Galphai-coupled receptors.

Highlights

  • ␤-Arrestin1 is an adapter/scaffold for many G proteincoupled receptors during mitogen-activated protein kinase signaling

  • We have recently shown that insulin treatment leads to ␤-arrestin1 degradation [10] as well as increased ␤-arrestin1 Ser-412 nase/ERK kinase; HIRc, human insulin receptor cDNA; ST, small t antigen; insulin-like growth factor-1 (IGF-1), insulin-like growth factor 1; IGF-1R, IGF-1 receptor; PBS, phosphate-buffered saline; PKA, cAMP-dependent protein kinase; SOS, son-of-sevenless

  • Insulin Treatment Leads to a Time- and Dose-dependent Increase of ␤-Arrestin1 Ser-412 Phosphorylation—We have previously shown that insulin treatment (100 ng/ml) for 8 –12 h leads to proteasomally mediated degradation of ␤-arrestin1, reducing cellular ␤-arrestin1 function [10]

Read more

Summary

THE JOURNAL OF BIOLOGICAL CHEMISTRY

Vol 280, No 2, Issue of January 14, pp. 1016 –1023, 2005 Printed in U.S.A. Insulin-induced ␤-Arrestin Ser-412 Phosphorylation Is a Mechanism for Desensitization of ERK Activation by G␣i-coupled Receptors*. Insulin treatment caused increased ␤-arrestin Ser-412 phosphorylation, which blocked mitogen-activated protein kinase signaling and internalization by ␤-arrestin1-dependent receptors with no effect on ␤-adrenergic receptor Gs-mediated cAMP production. These findings provide a new mechanism for insulin-induced desensitization of ERK activation by G␣icoupled receptors. Previous studies have described a role for ERK during Ser-412 phosphorylation [16, 20], while others have found the protein phosphatase 2A (PP2A) and PP2B in complexes that contain ␤-arrestin [21] In this regard, we have recently found that insulin-induced reduction of PP2A activity is involved in the desensitization of ERK signaling [22], but the role of PP2A in regulating ␤-arrestin Ser-412 phosphorylation has not been described. We demonstrate a novel role for PP2A in this process

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call